1. [CASE 1 — QUESTION 1]
A 63-year-old man with poorly controlled diabetes is admitted to the intensive care unit with influenza A pneumonia and acute hypoxemic respiratory failure requiring intubation and mechanical ventilation. He has an ileus with high nasogastric residuals, so enteral absorption is unreliable, and inhaled drug delivery is not feasible while he is ventilated. A nasopharyngeal swab confirms influenza A, and he was last well four days ago. Which antiviral choice best fits his clinical constraints?
A) Oral oseltamivir by nasogastric tube at standard dosing, because absorption is dependable in critical illness
B) Intravenous peramivir, because it bypasses both the unreliable enteral route and the impracticality of inhaled delivery in a ventilated patient
C) Inhaled zanamivir delivered through the ventilator circuit, because it concentrates drug in the lungs
D) Amantadine, because the oral route avoids the need for intravenous access
E) No antiviral, because treatment beyond 48 hours offers no benefit in any patient
ANSWER: B
Rationale:
Intravenous peramivir is the appropriate neuraminidase inhibitor here because it bypasses the unreliable enteral absorption caused by ileus and high residuals and avoids the impracticality of inhaled delivery during mechanical ventilation; severe, hospitalized influenza also warrants treatment regardless of the four-day duration.
Option A: Option A is incorrect: the scenario specifies unreliable enteral absorption, so nasogastric oseltamivir cannot be assumed to achieve therapeutic levels.
Option C: Option C is incorrect: inhaled zanamivir is not designed for ventilator-circuit delivery and is inappropriate in this setting.
Option D: Option D is incorrect: amantadine is clinically obsolete for influenza because of near-universal M2 resistance, regardless of route.
Option E: Option E is incorrect: hospitalized and severe influenza should be treated even beyond 48 hours, so withholding antivirals is wrong.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. Over the next day he develops acute kidney injury, with creatinine clearance falling to approximately 25 mL/min while he remains on intravenous peramivir. How should this change in renal function affect his antiviral management?
A) No change is required, because peramivir is eliminated entirely by hepatic metabolism
B) Peramivir should be discontinued and replaced by inhaled zanamivir, which requires no dosing changes in any circumstance
C) The peramivir dose should be reduced according to renal function, because peramivir is renally cleared and will otherwise accumulate
D) The peramivir dose should be doubled to overcome reduced delivery to the lungs
E) Antiviral therapy should be stopped because acute kidney injury contraindicates all neuraminidase inhibitors
ANSWER: C
Rationale:
Peramivir is renally cleared, so a substantial fall in creatinine clearance requires a dose reduction to prevent accumulation; renal dose adjustment, not discontinuation, is the correct response.
Option A: Option A is incorrect: peramivir is eliminated renally rather than by hepatic metabolism, so renal function does affect dosing.
Option B: Option B is incorrect: the patient is intubated, so inhaled zanamivir is impractical, and the premise that zanamivir never needs dosing consideration ignores the clinical setting.
Option D: Option D is incorrect: the issue is reduced renal elimination, not reduced pulmonary delivery, so doubling the dose would worsen accumulation.
Option E: Option E is incorrect: acute kidney injury calls for dose adjustment, not blanket discontinuation, and treating severe influenza remains important.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. Despite several days of appropriately dosed intravenous peramivir he continues to shed virus and remains febrile. Genotyping of the influenza A isolate reveals the H275Y neuraminidase substitution. Which interpretation and action are most appropriate?
A) H275Y confers high-level resistance that compromises peramivir and oseltamivir but characteristically spares zanamivir; transition to a zanamivir-based regimen (including investigational intravenous zanamivir where available) is the rational next step
B) H275Y confers resistance only to baloxavir, so switching to any neuraminidase inhibitor will restore efficacy
C) H275Y abolishes neuraminidase activity, so the virus is no longer replication-competent and antivirals can simply be stopped
D) H275Y is an M2 mutation, so adding amantadine will overcome it
E) H275Y guarantees complete resistance to every influenza antiviral, so only supportive care remains
ANSWER: A
Rationale:
H275Y is the principal N1 neuraminidase resistance substitution; it confers high-level resistance affecting oseltamivir and reduces peramivir activity while characteristically sparing zanamivir, so transition to a zanamivir-based regimen — including investigational intravenous zanamivir where available — is the rational step in a patient failing peramivir.
Option B: Option B is incorrect: H275Y is a neuraminidase mutation, not a baloxavir-target mutation, and it does not spare all neuraminidase inhibitors equally.
Option C: Option C is incorrect: H275Y alters drug binding without abolishing enzymatic activity, so the virus remains replication-competent and continues shedding.
Option D: Option D is incorrect: H275Y is a neuraminidase substitution, not an M2 mutation, and adamantanes are obsolete because of universal M2 resistance.
Option E: Option E is incorrect: H275Y does not confer pan-resistance; zanamivir-based options typically remain effective, and baloxavir at a different target is also available.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. Given severe, prolonged influenza with documented neuraminidase resistance, the team considers adding baloxavir to a zanamivir-based regimen. What is the strongest mechanistic rationale for combining these agents in severe influenza?
A) The two agents share the neuraminidase target, so combining them simply intensifies inhibition at that one site
B) Zanamivir is required to activate baloxavir from its prodrug form
C) The combination is antagonistic because both drugs compete for the polymerase acidic subunit
D) Baloxavir inhibits the polymerase acidic subunit cap-dependent endonuclease while the neuraminidase inhibitor blocks virion release, so attacking two distinct replication steps may improve suppression and reduce the chance that a single resistance substitution defeats therapy
E) Baloxavir replaces the need for any neuraminidase inhibitor because it also blocks neuraminidase
ANSWER: D
Rationale:
Baloxavir acts at the polymerase acidic subunit cap-dependent endonuclease (an early transcription step) while a neuraminidase inhibitor blocks virion release (a late step); attacking two distinct steps can enhance viral suppression in severe disease and reduces the likelihood that a single resistance substitution defeats both drugs, which is the rationale for investigating such combinations.
Option A: Option A is incorrect: the two agents do not share a target, so the premise of intensifying inhibition at one site is wrong.
Option B: Option B is incorrect: baloxavir is activated by arylacetamide deacetylase independently of zanamivir.
Option C: Option C is incorrect: the drugs act at different targets and do not compete at the polymerase acidic subunit, so they are not antagonistic.
Option E: Option E is incorrect: baloxavir does not block neuraminidase; it targets the polymerase, so it does not substitute for a neuraminidase inhibitor.
5. [CASE 2 — QUESTION 1]
A 49-year-old woman receiving induction chemotherapy for acute leukemia is profoundly neutropenic when she develops influenza A. She is started promptly on oral oseltamivir, but two weeks later she still has low-grade fever and persistently positive influenza testing. Which statement best explains the elevated risk of antiviral resistance in this clinical situation?
A) Immunocompromised patients clear virus faster, so prolonged shedding indicates a laboratory error rather than ongoing replication
B) Resistance cannot emerge during a single patient's course because resistant variants only arise through reassortment between strains
C) Oseltamivir induces de novo resistance mutations that would not otherwise exist in the viral population
D) Resistance is impossible while a patient remains on therapy, because drug pressure prevents any viral replication
E) Prolonged high-level viral replication under sustained drug pressure in an immunocompromised host favors selection of pre-existing resistant variants, such as neuraminidase H275Y, increasing the likelihood of treatment-emergent resistance
ANSWER: E
Rationale:
Immunocompromised patients cannot clear virus efficiently, so replication continues for prolonged periods under sustained drug pressure; this favors selection of pre-existing resistant variants such as H275Y, which is why treatment-emergent resistance is more common in this population.
Option A: Option A is incorrect: immunocompromised patients clear virus more slowly, not faster, and persistent positivity reflects ongoing replication.
Option B: Option B is incorrect: resistance can be selected within a single prolonged course; reassortment is a separate antigenic-shift phenomenon.
Option C: Option C is incorrect: drug selects pre-existing variants generated by error-prone replication rather than inducing new mutations.
Option D: Option D is incorrect: drug pressure does not abolish replication in a host who cannot mount effective immunity, so resistance can indeed emerge.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. Resistance testing confirms an H275Y substitution in the neuraminidase gene. She can use inhaled medication and has no airway disease. Which change in therapy is most appropriate?
A) Continue oseltamivir at the same dose, since H275Y does not meaningfully reduce its activity
B) Switch to inhaled zanamivir (or intravenous peramivir if the inhaled route becomes unsuitable), because H275Y characteristically preserves zanamivir susceptibility
C) Add amantadine, since adamantanes are active against H275Y-bearing strains
D) Stop antivirals, since H275Y confers resistance to all influenza drugs
E) Substitute palivizumab, which neutralizes resistant influenza
ANSWER: B
Rationale:
H275Y confers high-level oseltamivir resistance but characteristically spares zanamivir because the two drugs contact the active site differently; switching to inhaled zanamivir (with intravenous peramivir as an alternative if needed) is the rational rescue in a patient who can use the inhaled route.
Option A: Option A is incorrect: H275Y produces high-level oseltamivir resistance, so continuing the same dose is ineffective.
Option C: Option C is incorrect: adamantanes are obsolete for influenza because of universal M2 resistance and have no role here.
Option D: Option D is incorrect: H275Y does not confer pan-resistance; zanamivir and often peramivir remain active, and baloxavir at a different target is also available.
Option E: Option E is incorrect: palivizumab is an anti-respiratory syncytial virus monoclonal antibody with no influenza activity.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. The team also considers baloxavir, reasoning that its different target should be unaffected by the neuraminidase mutation. Which statement most accurately frames the use of baloxavir in this prolonged, immunocompromised infection?
A) Baloxavir will be inactive because H275Y also reduces binding at the polymerase acidic subunit
B) Baloxavir cannot be combined with a neuraminidase inhibitor because they share a binding site
C) Baloxavir is contraindicated whenever any neuraminidase resistance is present
D) Baloxavir should retain activity because it targets the polymerase acidic subunit endonuclease rather than neuraminidase, but prolonged replication in an immunocompromised host raises the risk of treatment-emergent PA-I38 substitutions, so monitoring for emerging baloxavir resistance is warranted
E) Baloxavir provides durable immunity after one dose, eliminating any concern about further replication
ANSWER: D
Rationale:
Baloxavir acts at the polymerase acidic subunit cap-dependent endonuclease, a target unaffected by the neuraminidase H275Y mutation, so it should retain activity; however, prolonged replication in an immunocompromised host raises the risk of treatment-emergent PA-I38 substitutions, so monitoring for emerging baloxavir resistance is appropriate.
Option A: Option A is incorrect: H275Y is a neuraminidase mutation and does not reduce binding at the polymerase acidic subunit.
Option B: Option B is incorrect: baloxavir and neuraminidase inhibitors act at different targets and can be combined; they do not share a binding site.
Option C: Option C is incorrect: neuraminidase resistance is in fact a reason baloxavir may be useful, not a contraindication.
Option E: Option E is incorrect: baloxavir does not confer immunity, and replication can continue, especially in an immunocompromised host.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. Infection control asks whether the H275Y-resistant virus she harbors is likely to spread widely among other patients on the unit. Applying the principle of fitness cost, which assessment is most accurate?
A) Whether a resistance mutation spreads depends chiefly on its fitness cost; most neuraminidase H275Y variants historically carried enough fitness cost to limit spread, though a notable exception in 2008 to 2009 spread efficiently, so transmissibility cannot be assumed to be negligible and standard infection-control precautions remain essential
B) The resistant strain will certainly spread to near-universal prevalence, because every resistance mutation eventually dominates the population
C) The resistant strain cannot spread at all, because resistance mutations are always lethal to the virus
D) Spread is determined solely by how many patients receive oseltamivir, independent of viral fitness
E) Fitness cost is irrelevant to transmission, which depends only on antigenic drift
ANSWER: A
Rationale:
Whether a resistance mutation spreads is governed chiefly by its fitness cost. Many H275Y variants historically carried sufficient fitness cost to limit spread, but the 2008 to 2009 seasonal H1N1 experience showed an H275Y strain that spread efficiently without a fitness deficit, so transmissibility cannot be assumed negligible and standard infection-control precautions remain essential.
Option B: Option B is incorrect: not every resistance mutation dominates; high-fitness-cost variants spread poorly.
Option C: Option C is incorrect: H275Y alters binding without abolishing replication, so it is not lethal to the virus.
Option D: Option D is incorrect: spread depends on viral fitness, not solely on prescribing volume.
Option E: Option E is incorrect: fitness cost is central to transmission of resistant variants; antigenic drift is a separate phenomenon.
9. [CASE 3 — QUESTION 1]
A 54-year-old kidney transplant recipient maintained on tacrolimus and mycophenolate presents with two days of cough and fever and tests positive for SARS-CoV-2. She is at high risk for progression and is being considered for nirmatrelvir-ritonavir. What is the most important pharmacologic consideration before prescribing it?
A) No special consideration is needed, because ritonavir affects only the concentration of nirmatrelvir
B) The tacrolimus dose should be increased during therapy to maintain immunosuppression
C) Ritonavir is a potent CYP3A4 inhibitor and tacrolimus is cleared by CYP3A4, so coadministration can cause a marked rise in tacrolimus levels and toxicity; the interaction must be actively managed with dose holding or modification and close level monitoring, or an alternative antiviral chosen
D) Nirmatrelvir-ritonavir is absolutely contraindicated in all transplant recipients and can never be used
E) Mycophenolate will inactivate ritonavir, so the antiviral dose should be doubled
ANSWER: C
Rationale:
Ritonavir potently inhibits CYP3A4, the enzyme that clears tacrolimus, so coadministration can cause a marked, potentially toxic rise in tacrolimus concentrations; the interaction must be actively managed — typically by holding or modifying tacrolimus with close level monitoring under specialist guidance — or an alternative antiviral such as remdesivir chosen.
Option A: Option A is incorrect: ritonavir's CYP3A4 inhibition affects any CYP3A4 substrate, including tacrolimus, not only nirmatrelvir.
Option B: Option B is incorrect: ritonavir raises tacrolimus levels, so increasing the dose would compound toxicity.
Option D: Option D is incorrect: the combination is not absolutely contraindicated in transplant recipients; the interaction is managed rather than prohibited.
Option E: Option E is incorrect: mycophenolate does not inactivate ritonavir, and doubling the antiviral is not an appropriate response.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. To avoid the tacrolimus interaction, the team selects remdesivir. Which description of remdesivir's mechanism is correct?
A) It inhibits the SARS-CoV-2 main protease, preventing cleavage of the viral polyprotein
B) It inhibits CYP3A4 to raise the concentration of a partner antiviral
C) It is a monoclonal antibody that neutralizes the spike protein
D) It blocks the cap-dependent endonuclease of the viral polymerase
E) It is a phosphoramidate prodrug of an adenosine analogue that, after intracellular activation to its triphosphate, is incorporated by the viral RNA-dependent RNA polymerase and causes delayed chain termination a few nucleotides downstream
ANSWER: E
Rationale:
Remdesivir is a phosphoramidate prodrug of an adenosine analogue; after activation to its triphosphate it is incorporated by the viral RNA-dependent RNA polymerase and produces delayed chain termination a few nucleotides downstream, halting genome synthesis — a mechanism unrelated to CYP3A4, so it avoids the tacrolimus interaction.
Option A: Option A is incorrect: main-protease inhibition describes nirmatrelvir, not remdesivir.
Option B: Option B is incorrect: CYP3A4 inhibition to boost a partner drug describes ritonavir.
Option C: Option C is incorrect: remdesivir is a small-molecule nucleotide analogue, not a monoclonal antibody.
Option D: Option D is incorrect: cap-dependent endonuclease inhibition describes baloxavir, an influenza polymerase inhibitor, not remdesivir.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. She is admitted and requires 2 liters per minute of supplemental oxygen by nasal cannula but is not on high-flow oxygen or mechanical ventilation. How does her clinical stage relate to the expected benefit of remdesivir?
A) Benefit is greatest only once she progresses to mechanical ventilation, when viral replication peaks
B) Benefit is most likely at her current stage — hospitalized on low-flow oxygen without progression to mechanical ventilation — because remdesivir suppresses viral replication and is most useful earlier in the course before severe inflammation predominates
C) Remdesivir provides no benefit in any hospitalized patient and is reserved exclusively for outpatients
D) Remdesivir works mainly by suppressing inflammation, so its benefit increases as inflammation worsens late in disease
E) Requiring supplemental oxygen is a contraindication to remdesivir
ANSWER: B
Rationale:
The clearest measurable inpatient benefit of remdesivir is in patients on low-flow supplemental oxygen who have not progressed to mechanical ventilation; because it suppresses viral replication, its benefit concentrates earlier in the course before severe inflammation dominates, which matches her current stage.
Option A: Option A is incorrect: benefit is less clear once mechanical ventilation is required, so waiting for that stage is the opposite of the rationale.
Option C: Option C is incorrect: remdesivir is used in hospitalized patients, not only outpatients.
Option D: Option D is incorrect: remdesivir is an antiviral, not primarily an anti-inflammatory, so benefit does not increase with worsening late inflammation.
Option E: Option E is incorrect: requiring supplemental oxygen is an indication, not a contraindication, for inpatient remdesivir.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. A colleague recalls that some patients treated with nirmatrelvir-ritonavir experience a recurrence of symptoms and a rise in viral load after finishing the standard course. Which statement best characterizes this phenomenon?
A) Rebound of COVID-19 symptoms and viral load after completion of the standard five-day nirmatrelvir-ritonavir course has been reported, its mechanism remains under investigation, and it does not by itself establish drug resistance
B) Rebound proves that the virus has acquired high-level resistance to nirmatrelvir and mandates lifelong retreatment
C) Rebound occurs because ritonavir permanently induces CYP3A4, accelerating clearance of the antiviral
D) Rebound is unique to remdesivir and never occurs after nirmatrelvir-ritonavir
E) Rebound indicates that the patient was never actually infected with SARS-CoV-2
ANSWER: A
Rationale:
Rebound of symptoms and viral load after the standard five-day nirmatrelvir-ritonavir course has been reported; its mechanism remains under investigation and it does not, by itself, establish that the virus has become resistant.
Option B: Option B is incorrect: rebound is not evidence of high-level resistance and does not mandate lifelong retreatment.
Option C: Option C is incorrect: ritonavir inhibits rather than permanently induces CYP3A4, so this is not the explanation for rebound.
Option D: Option D is incorrect: rebound is described after nirmatrelvir-ritonavir, so attributing it uniquely to remdesivir is wrong.
Option E: Option E is incorrect: rebound occurs in genuinely infected patients and does not imply absence of infection.
13. [CASE 4 — QUESTION 1]
A healthy full-term infant is brought to clinic at 6 weeks of age in early October, just as the respiratory syncytial virus season begins. The parents want to reduce the risk of severe respiratory syncytial virus disease. The infant has received no prior respiratory syncytial virus prevention. What is the most appropriate recommendation?
A) Begin monthly palivizumab injections through the season, as palivizumab is first-line for all healthy term infants
B) Start oral ribavirin as seasonal prophylaxis
C) Give an influenza neuraminidase inhibitor for cross-protection against respiratory syncytial virus
D) Administer a single dose of nirsevimab, a long-acting monoclonal antibody recommended for infants under eight months entering their first respiratory syncytial virus season, providing season-long protection
E) Provide no prevention, because monoclonal antibodies are restricted to premature infants only
ANSWER: D
Rationale:
Nirsevimab is recommended for all infants under eight months entering their first respiratory syncytial virus season; a single dose provides season-long protection, making it the appropriate choice for this healthy term infant.
Option A: Option A is incorrect: palivizumab requires monthly dosing and is now reserved for defined high-risk groups rather than being first-line for healthy term infants.
Option B: Option B is incorrect: ribavirin is not used for routine respiratory syncytial virus prophylaxis.
Option C: Option C is incorrect: influenza neuraminidase inhibitors have no activity against respiratory syncytial virus.
Option E: Option E is incorrect: nirsevimab is recommended broadly for infants entering their first season, not only premature infants.
14. [CASE 4 — QUESTION 2]
Continuing with the same infant. The parents ask how a single injection can protect for an entire season and why newer antibodies are more potent than older ones. Which explanation is most accurate?
A) Nirsevimab binds a prefusion-specific epitope of the fusion protein — a conformation that elicits substantially more potent neutralization than the postfusion form — and is engineered with an extended-half-life Fc region that sustains protective levels across an entire season from one dose
B) Nirsevimab binds the postfusion conformation of the fusion protein, which is the most potent neutralizing target, and must be redosed monthly
C) Nirsevimab targets the attachment glycoprotein and stimulates the infant's own durable antibody production
D) Nirsevimab inhibits the viral polymerase, which is why a single dose suffices
E) Nirsevimab is a small-molecule fusion inhibitor whose prolonged tissue binding explains single-season dosing
ANSWER: A
Rationale:
Antibodies that bind the prefusion conformation of the fusion protein neutralize far more potently than those targeting the postfusion form; nirsevimab binds a prefusion-specific epitope and carries an engineered extended-half-life Fc region, so a single dose maintains protective concentrations across the season.
Option B: Option B is incorrect: prefusion, not postfusion, binding is the more potent strategy, and nirsevimab is dosed once rather than monthly.
Option C: Option C is incorrect: nirsevimab targets the fusion protein and provides passive immunity, not active antibody production by the infant.
Option D: Option D is incorrect: nirsevimab is an antibody against the fusion protein, not a polymerase inhibitor.
Option E: Option E is incorrect: nirsevimab is a monoclonal antibody, not a small molecule, and its dosing reflects Fc engineering rather than tissue retention of a small molecule.
15. [CASE 4 — QUESTION 3]
Continuing with the same infant. The parents ask whether the injection is a vaccine that will train the infant's immune system. Which statement most accurately characterizes the type of protection nirsevimab provides?
A) It is a live attenuated vaccine that establishes lifelong active immunity after a single dose
B) It is a toxoid vaccine that requires a booster series to be effective
C) It stimulates the infant to produce its own neutralizing antibodies over several weeks before protection begins
D) It provides no real protection until the infant mounts an independent immune response
E) It provides passive immunity — preformed monoclonal antibody that confers immediate protection that wanes over months as the antibody is cleared — rather than active immunity generated by the infant's own immune system
ANSWER: E
Rationale:
Nirsevimab is a monoclonal antibody that supplies preformed neutralizing antibody, conferring immediate passive protection that wanes over months as the antibody is cleared; it does not train the infant's immune system to generate its own response.
Option A: Option A is incorrect: nirsevimab is not a live attenuated vaccine and does not establish active lifelong immunity.
Option B: Option B is incorrect: it is not a toxoid vaccine and does not work through a booster series.
Option C: Option C is incorrect: passive antibody acts immediately and does not depend on the infant producing antibodies over weeks.
Option D: Option D is incorrect: passive immunity provides real, immediate protection without requiring the infant's own immune response.
16. [CASE 4 — QUESTION 4]
Continuing with the same family. At a later visit they bring the infant's older sibling, who was born at 28 weeks and has chronic lung disease of prematurity still requiring medical therapy, now entering the respiratory syncytial virus season; the clinic's nirsevimab supply is temporarily exhausted. Which prophylactic option retains an established, guideline-supported role for this high-risk child?
A) Oral oseltamivir prophylaxis through the season
B) Aerosolized ribavirin as a single prophylactic dose
C) Monthly intramuscular palivizumab through the respiratory syncytial virus season, which remains indicated for high-risk groups such as chronic lung disease of prematurity requiring ongoing medical therapy
D) No prophylaxis, because palivizumab has been completely withdrawn from use
E) An influenza vaccine, which also covers respiratory syncytial virus
ANSWER: C
Rationale:
Palivizumab retains an established role for specific high-risk infants — including chronic lung disease of prematurity requiring ongoing medical therapy — given as monthly intramuscular injections through the season, making it the appropriate option when nirsevimab is unavailable.
Option A: Option A is incorrect: oseltamivir is an influenza drug with no respiratory syncytial virus activity.
Option B: Option B is incorrect: aerosolized ribavirin is a treatment reserved for selected severe disease, not a prophylactic strategy.
Option D: Option D is incorrect: palivizumab has not been withdrawn; it remains indicated for defined high-risk groups.
Option E: Option E is incorrect: influenza vaccine does not protect against respiratory syncytial virus.
17. [CASE 5 — QUESTION 1]
A 31-year-old woman who is 24 weeks pregnant presents with one day of fever, cough, and myalgias during peak influenza season. She has no airway disease and normal renal function, and a rapid test confirms influenza A. Which antiviral is the most appropriate first choice?
A) Baloxavir, because its single-dose convenience makes it the preferred agent in pregnancy
B) Oseltamivir, because it is the preferred influenza antiviral in pregnancy, has the most accumulated safety experience, and should be started promptly given onset within 48 hours
C) Amantadine, because it is safe and effective against current influenza A strains in pregnancy
D) Aerosolized ribavirin, because it is well tolerated in pregnancy
E) No antiviral, because all influenza antivirals are contraindicated in pregnancy
ANSWER: B
Rationale:
Oseltamivir is the preferred influenza antiviral in pregnancy, with the greatest accumulated safety experience, and prompt initiation within 48 hours is appropriate given her recent onset and the elevated risk influenza carries in pregnancy.
Option A: Option A is incorrect: baloxavir is not recommended in pregnancy because of limited data, so convenience does not make it preferred.
Option C: Option C is incorrect: amantadine is clinically obsolete for influenza because of near-universal resistance.
Option D: Option D is incorrect: ribavirin is teratogenic and is not an influenza treatment, so it is contraindicated in pregnancy.
Option E: Option E is incorrect: influenza antivirals are not all contraindicated in pregnancy; oseltamivir is recommended, and untreated influenza poses real risk.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. Local surveillance reports that the circulating influenza A strain carries the oseltamivir-conferring H275Y substitution. She has no asthma or other airway disease. Considering both the resistance pattern and her pregnancy, which option is most defensible?
A) Standard-dose oseltamivir, because pregnancy outweighs the resistance concern
B) Amantadine, because adamantane and neuraminidase resistance never coexist
C) Baloxavir, because it is the preferred influenza agent in pregnancy
D) Inhaled zanamivir, because H275Y characteristically preserves zanamivir susceptibility and the neuraminidase inhibitors have a more established pregnancy safety record than baloxavir, while she has no airway disease that would contraindicate the inhaled route
E) Aerosolized ribavirin, because it is the safest antiviral in pregnancy
ANSWER: D
Rationale:
H275Y characteristically spares zanamivir, so it remains active against this strain, and the neuraminidase inhibitors have a more established pregnancy safety record than baloxavir; with no airway disease to contraindicate the inhaled route, inhaled zanamivir is a defensible choice.
Option A: Option A is incorrect: H275Y confers high-level oseltamivir resistance, so standard-dose oseltamivir is unlikely to be effective.
Option B: Option B is incorrect: adamantanes are obsolete because of near-universal M2 resistance, and the claim that the two resistance types never coexist is false.
Option C: Option C is incorrect: baloxavir is not preferred in pregnancy because of limited data.
Option E: Option E is incorrect: ribavirin is teratogenic and is not an influenza treatment, so it is not a safe option in pregnancy.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. Suppose instead she had presented on day 3 of symptoms rather than day 1. How should the timing of presentation affect the decision to treat her?
A) Treatment should be withheld because benefit is uniformly absent beyond 48 hours in all patients
B) Treatment should be deferred until the viral replication peak passes to avoid selecting resistance
C) Treatment is still warranted because pregnancy is itself a high-risk condition for severe influenza, and antiviral benefit persists beyond 48 hours in high-risk patients
D) Treatment should be limited to antipyretics, since antivirals are unsafe after 48 hours in pregnancy
E) Treatment should switch to a vaccine, which provides faster protection than an antiviral at this stage
ANSWER: C
Rationale:
Pregnancy is itself a high-risk condition for severe influenza, and antiviral benefit persists beyond 48 hours in high-risk patients, so a pregnant patient presenting on day 3 should still be treated.
Option A: Option A is incorrect: benefit is not uniformly absent beyond 48 hours; it persists in high-risk groups.
Option B: Option B is incorrect: deferring to await the replication peak contradicts the principle of suppressing active replication promptly, especially in a high-risk patient.
Option D: Option D is incorrect: antivirals are not unsafe after 48 hours in pregnancy, and limiting care to antipyretics is inadequate for a high-risk patient.
Option E: Option E is incorrect: a vaccine does not provide rapid treatment of established influenza and does not substitute for antiviral therapy here.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. After her recovery, her household includes a high-risk elderly grandparent who has just had close unprotected exposure to another influenza case and for whom post-exposure chemoprophylaxis with oseltamivir is being considered. How does the prophylaxis regimen differ from the treatment regimen?
A) Prophylaxis uses a higher dose given more frequently than treatment to prevent infection
B) Prophylaxis and treatment use identical regimens in every respect
C) Prophylaxis requires intravenous administration, whereas treatment is oral
E) Prophylaxis uses the same unit dose given once daily — a lower total daily dose than the twice-daily treatment regimen — and is continued for the defined post-exposure period
ANSWER: E
Rationale:
Oseltamivir chemoprophylaxis uses the same unit dose given once daily, which is a lower total daily dose than the twice-daily treatment regimen, continued for the defined post-exposure period.
Option A: Option A is incorrect: prophylaxis uses a lower total daily dose (once daily), not a higher, more frequent dose.
Option B: Option B is incorrect: the regimens are not identical; dosing frequency differs.
Option C: Option C is incorrect: oseltamivir is oral for both prophylaxis and treatment.
Option D: Option D is incorrect: amantadine is obsolete for influenza, and prophylaxis uses oseltamivir, not amantadine.
21. [CASE 6 — QUESTION 1]
A 26-year-old healthy man presents 20 hours after the onset of acute uncomplicated influenza and wants the simplest effective regimen. He weighs 70 kg and has no comorbidities. He is prescribed a single oral dose of baloxavir. Which property of baloxavir most directly supports single-dose therapy?
A) Its active acid has a long plasma half-life of approximately 79 hours, so a single dose maintains effective concentrations across the treatment window
B) It is eliminated within a few hours, so additional doses would be redundant
C) It is stored in respiratory tissue and released only when viral replication is detected
D) It permanently inactivates the polymerase, so the virus can never resume replication after one exposure
E) It generates durable immunity after one dose, removing any need for further drug
ANSWER: A
Rationale:
Baloxavir acid has a long plasma half-life of approximately 79 hours, so a single dose sustains effective concentrations across the period of active influenza replication, which is the pharmacokinetic basis for single-dose therapy.
Option B: Option B is incorrect: rapid elimination would argue for more frequent dosing, the opposite of baloxavir's profile.
Option C: Option C is incorrect: baloxavir is not a tissue depot released on demand; single dosing reflects its long half-life.
Option D: Option D is incorrect: baloxavir reversibly inhibits the endonuclease and does not permanently inactivate the polymerase; treatment-emergent resistance can occur.
Option E: Option E is incorrect: antivirals do not confer immunity, which is the role of vaccination.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. He asks how baloxavir differs from the flu medicine his roommate took (oseltamivir). Which description of baloxavir's mechanism is correct?
A) It competitively blocks the neuraminidase active site, preventing release of budding virions
B) It blocks the M2 ion channel, preventing the proton influx required for uncoating
C) It is incorporated into the growing viral RNA chain and terminates elongation
D) It binds hemagglutinin and prevents attachment to sialic acid receptors
E) It inhibits the cap-dependent endonuclease of the polymerase acidic subunit, blocking the cap-snatching step that primes viral messenger RNA synthesis, a mechanism distinct from neuraminidase inhibition
ANSWER: E
Rationale:
Baloxavir acid inhibits the cap-dependent endonuclease of the polymerase acidic subunit, blocking the cap-snatching step that primes viral messenger RNA synthesis; this is mechanistically distinct from oseltamivir, which competitively inhibits neuraminidase.
Option A: Option A is incorrect: competitive neuraminidase blockade describes oseltamivir, not baloxavir.
Option B: Option B is incorrect: M2 ion-channel blockade describes the adamantanes.
Option C: Option C is incorrect: incorporation into viral RNA with chain termination describes a nucleoside/nucleotide analogue such as remdesivir.
Option D: Option D is incorrect: baloxavir does not target hemagglutinin-mediated attachment.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. His symptoms initially improve but then linger longer than expected, and repeat testing shows continued viral shedding. A PA-I38T substitution is identified. Which interpretation and management are best?
A) PA-I38T abolishes neuraminidase activity, so the virus is no longer transmissible and no treatment is needed
B) PA-I38T reduces baloxavir binding at the cap-dependent endonuclease and can emerge during treatment, prolonging shedding; because it does not affect the neuraminidase target, a neuraminidase inhibitor such as oseltamivir or zanamivir remains an effective option if continued therapy is warranted
C) PA-I38T confers resistance to all influenza antivirals, so only supportive care remains
D) PA-I38T is an M2 mutation best addressed by adding amantadine
E) PA-I38T indicates oseltamivir resistance, so baloxavir should be continued at a higher dose
ANSWER: B
Rationale:
PA-I38T reduces baloxavir binding at the cap-dependent endonuclease and can emerge during treatment, prolonging viral shedding; because it affects the polymerase rather than neuraminidase, a neuraminidase inhibitor such as oseltamivir or zanamivir remains effective if continued therapy is warranted.
Option A: Option A is incorrect: PA-I38T is a polymerase substitution that does not abolish neuraminidase activity or transmissibility.
Option C: Option C is incorrect: PA-I38T affects only the baloxavir target, so it does not confer pan-resistance.
Option D: Option D is incorrect: PA-I38T is a polymerase acidic subunit substitution, not an M2 mutation, and adamantanes are obsolete.
Option E: Option E is incorrect: PA-I38T indicates reduced baloxavir, not oseltamivir, susceptibility, so escalating baloxavir is not the answer.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. He recalls an older relative once taking amantadine for the flu and asks why it was not offered to him, and whether his treatment would have worked had he been infected with influenza B instead. Which response is most accurate?
A) Amantadine remains a first-line option, and it would have worked equally well against influenza B
B) Amantadine is avoided only because it is inconvenient, but it is still fully active against current influenza A
C) Amantadine is avoided because it causes universal kidney failure, and influenza B is untreatable by any drug
D) Amantadine is not used because essentially all circulating influenza A strains carry the S31N M2 mutation that renders adamantanes ineffective, and adamantanes never had activity against influenza B because influenza B lacks the M2 channel; baloxavir, by contrast, is active against both influenza A and B
E) Amantadine is preferred for influenza B specifically, since influenza B is especially sensitive to M2 blockade
ANSWER: D
Rationale:
Adamantanes are not used because essentially all circulating influenza A strains carry the S31N M2 substitution that renders them ineffective, and they never had activity against influenza B, which lacks the M2 channel; baloxavir, by contrast, is active against both influenza A and B, so it would have been an appropriate choice regardless of type.
Option A: Option A is incorrect: amantadine is not first-line and has no activity against influenza B.
Option B: Option B is incorrect: the problem is near-universal resistance, not mere inconvenience, so amantadine is not fully active against current influenza A.
Option C: Option C is incorrect: adamantanes are avoided because of resistance, not universal renal failure, and influenza B is treatable with neuraminidase inhibitors and baloxavir.
Option E: Option E is incorrect: influenza B lacks the M2 channel, so it is not sensitive to adamantane M2 blockade.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.